Abstract
In HIV prevention trials, precise identification of infection time is critical to quantify drug efficacy but difficult to estimate as trials may have relatively sparse visit schedules. The last negative visit does not guarantee a boundary on infection time because viral nucleic acid is not present in the blood during early infection. Here, we developed a framework that combines stochastic and deterministic within-host mathematical modeling of viral dynamics accounting for the early unobservable viral load phase until it reaches a high chronic set point. The infection time estimation is based on a population non-linear mixed effects (pNLME) framework that includes the with-in host modeling. We applied this framework to viral load data from the RV217 trial and found a parsimonious model capable of recapitulating the viral loads. When adding the stochastic and deterministic portion of the best model, the estimated infection time for the RV217 data had an average of 2 weeks between infecting exposure and first positive. We assessed the sensitivity of the infection time estimation by conducting in silico studies with varying viral load sampling schemes before and after infection. pNLME accurately estimates infection times for a daily sampling scheme and is fairly robust to sparser schemes. For a monthly sampling scheme before and after first positive bias increases to -7 days. For pragmatic trial design, we found sampling weekly before and monthly after first positive allows accurate pNLME estimation. Our estimates can be used in parallel with other approaches that rely on viral sequencing, and because the model is mechanistic, it is primed for future application to infection timing for specific interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
DBR is funded by a Washington Research Foundation postdoctoral fellowship. Funding was also provided by the National Institute of Health NIAID (K25 AI155224 to DBR, UM1 AI068635 to PBG and JTS, R01 AI150500 to EFC and JTS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
RV217
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Added some funding information and fixed a middle initial.
Data Availability
All data and computational code are available from the authors and will be posted to github after acceptance.